Retatrutide Side Effects: What the Trials Show

The most common retatrutide side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. They tend to be mild to moderate, show up mostly during dose increases, and ease as your body adjusts. Trials have also tracked a modest rise in heart rate and, less often, changes in skin sensation at higher doses. Because retatrutide is still investigational and not FDA approved, its long-term safety picture is still being filled in. Here’s what the published Phase 2 data and the newer Phase 3 results actually show, and how the profile compares to the GLP-1 medications you can get today.

Is Retatrutide Safe?

Retatrutide is a triple-hormone-receptor agonist (it acts on the GLP-1, GIP, and glucagon receptors) being developed by Eli Lilly. In its Phase 2 trial, the rate of serious adverse events was similar between retatrutide and placebo, and most side effects were mild to moderate. The overall pattern looks a lot like the approved GLP-1 medications, with a few distinctive signals tied to the glucagon part of the mechanism. That said, “safe so far in trials” is not the same as “fully characterized.” Long-term and cardiovascular outcomes are still being studied, and the drug is not available by prescription anywhere.

The Most Common Side Effects: Digestive Symptoms

By a wide margin, the side effects people experience most are digestive. Retatrutide slows how quickly the stomach empties, which is part of how it curbs appetite, and that same effect can cause nausea, vomiting, diarrhea, and constipation. These are dose-dependent, meaning they get more common as the dose goes up. In the Phase 2 trial, nausea ranged from roughly 14 percent of participants at the lowest dose to about 60 percent at the highest. Vomiting and diarrhea followed the same upward pattern with dose.

The reassuring part is timing. Most of these symptoms cluster around the weeks right after a dose increase and then settle as the body adapts. If you want the background on why these drugs affect digestion the way they do, our piece on how GLP-1 medications affect your gut health and microbiome covers it.

Consider this scenario: someone starts at a low dose and feels fine, then notices nausea return each time the dose steps up. That stop-and-start pattern, tied to escalation rather than the drug itself being intolerable, is exactly what the trials saw. Knowing it’s coming is half the battle, because many people quit right before their body would have adjusted.

Here’s how the most-reported effects break down at higher doses, based on the trial data:

Side Effects Linked to the Glucagon Component

Two of retatrutide’s side effects stand out because they come from the glucagon receptor, which semaglutide and tirzepatide don’t target.

Increased Heart Rate

In the Phase 2 trial, resting heart rate rose in a dose-dependent way, by roughly 5 to 10 beats per minute at the higher doses. It peaked around week 24 and then declined. That’s a bit higher than the 3 to 5 beats per minute typically seen with semaglutide and tirzepatide, and it traces back to glucagon nudging up metabolic rate. No cardiovascular events were attributed to this rise during the trial, but a dedicated cardiovascular outcomes study is underway to answer the question definitively. Anyone with a heart-rhythm condition would need close provider oversight.

Changes in Skin Sensation

About 7 percent of Phase 2 participants reported heightened skin sensitivity or unusual sensations like tingling, compared with 1 percent on placebo. None of those events were severe, and none led people to stop treatment. The newer Phase 3 data showed this more often, likely because the studies were larger and ran longer. It’s a relatively novel finding for this drug class, which is one reason researchers are watching it closely.

Less Common but Important Considerations

A few rarer findings are worth knowing. In Phase 2, some participants had asymptomatic increases in the pancreatic enzymes amylase and lipase, and there was one case of acute pancreatitis. Pancreatitis is a known consideration for this whole drug class, so severe stomach pain that radiates to the back is always a reason to seek medical care promptly. Clinically significant low blood sugar was not seen in the trial, which is notable given glucagon’s role, though that risk would rise if the drug were combined with insulin or certain diabetes medications. As with any rapid weight loss, there can also be a higher chance of gallstones over time.

How Retatrutide Compares to Ozempic and Zepbound

For the digestive side effects, retatrutide looks broadly similar to the semaglutide and tirzepatide medications already on the market, and the share of people who stopped treatment because of side effects was in a comparable range. The real differences are the heart-rate bump and the skin-sensation signal, both from the glucagon arm. If you want a sense of how two approved options stack up on tolerability, our comparison of tirzepatide vs semaglutide side effects is a useful reference point.

Managing Side Effects: What the Trials Suggest

The single biggest lever is slow dose escalation. Because most symptoms cluster around dose increases and fade with time, moving up gradually gives the body room to adjust. Staying hydrated and eating smaller, lighter meals during those transition weeks tends to help. Some people also feel more tired as they adapt, which our overview of GLP-1 medications and energy levels puts in context. Only a minority of trial participants stopped because of side effects, but tolerability is individual, which is exactly why this kind of medication belongs under medical supervision.

What This Means If You’re Considering Weight Loss Now

Retatrutide’s side-effect profile is encouraging, but it isn’t available, and “research-use-only” versions sold online carry their own risks because they skip the quality and dosing oversight of prescription medication. The good news is that the approved GLP-1 medications have well-mapped side effects and a clear playbook for managing them. TrimRx offers physician-prescribed tirzepatide with provider guidance through the whole process, so side effects are handled by someone watching your case rather than left to guesswork.

Not sure what fits your health history? You can start your assessment to see which option makes sense for you, and follow retatrutide as more Phase 3 safety data arrives.

This article is for educational purposes and is not medical advice. Retatrutide is an investigational medication that is not FDA approved and is not available by prescription. Consult a licensed healthcare provider before starting or changing any treatment, and seek immediate medical attention for severe symptoms such as persistent, severe abdominal pain. Individual results vary.